AdComJul 13, 2026
FDA advisory — U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (v…▸
high impact
FilingJul 13, 2026
Regulatory filing — BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation▸
medium impact
Data +Jun 23, 2026
Positive data — BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment▸
high impact
DealJun 08, 2026
Deal — Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years▸
medium impact
Data +Jun 05, 2026
Positive data — BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story▸
high impact
Data +May 30, 2026
Positive data — BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development▸
high impact
Data +May 21, 2026
Positive data — BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint▸
high impact
Data +May 20, 2026
Positive data — BioMarin (BMRN) Is Down 6.3% After Mixed Phase 3 BMN 401 Results in ENPP1 Deficiency▸
high impact
EarningsMay 04, 2026
Q1 2026 report-2.4%muted
DealMay 04, 2026
Deal — BioMarin Pharmaceutical Q1 Earnings Call Highlights▸
medium impact
DealApr 27, 2026
Deal — BioMarin Completes Acquisition of Amicus Therapeutics▸
medium impact
EarningsFeb 23, 2026
FY 2025 report-2.9%muted
EarningsJan 26, 2026
FY 2025 report+0.4%muted
EarningsJan 12, 2026
FY 2025 report-4.6%negative
EarningsOct 27, 2025
Q3 2025 report-1.4%muted
EarningsOct 07, 2025
Q3 2025 report-4.4%negative
EarningsAug 04, 2025
Q2 2025 report-1.4%muted
EarningsMay 01, 2025
Q1 2025 report-4.9%negative
EarningsFeb 19, 2025
FY 2024 report+5.2%positive
EarningsOct 29, 2024
Q3 2024 report-4.7%negative
EarningsAug 05, 2024
Q2 2024 report+9.2%positive